JP2018100243A5 - - Google Patents

Download PDF

Info

Publication number
JP2018100243A5
JP2018100243A5 JP2016247814A JP2016247814A JP2018100243A5 JP 2018100243 A5 JP2018100243 A5 JP 2018100243A5 JP 2016247814 A JP2016247814 A JP 2016247814A JP 2016247814 A JP2016247814 A JP 2016247814A JP 2018100243 A5 JP2018100243 A5 JP 2018100243A5
Authority
JP
Japan
Prior art keywords
composition
cancer
administered
composition according
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016247814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018100243A (ja
JP7096639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2016247814A priority Critical patent/JP7096639B2/ja
Priority claimed from JP2016247814A external-priority patent/JP7096639B2/ja
Publication of JP2018100243A publication Critical patent/JP2018100243A/ja
Publication of JP2018100243A5 publication Critical patent/JP2018100243A5/ja
Application granted granted Critical
Publication of JP7096639B2 publication Critical patent/JP7096639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016247814A 2016-12-21 2016-12-21 テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法 Active JP7096639B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016247814A JP7096639B2 (ja) 2016-12-21 2016-12-21 テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016247814A JP7096639B2 (ja) 2016-12-21 2016-12-21 テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法

Publications (3)

Publication Number Publication Date
JP2018100243A JP2018100243A (ja) 2018-06-28
JP2018100243A5 true JP2018100243A5 (enExample) 2020-01-30
JP7096639B2 JP7096639B2 (ja) 2022-07-06

Family

ID=62714976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016247814A Active JP7096639B2 (ja) 2016-12-21 2016-12-21 テロメラーゼ由来のペプチドを含む樹状細胞治療剤及び免疫治療剤、及びこれを用いる治療方法

Country Status (1)

Country Link
JP (1) JP7096639B2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518216B (zh) * 2019-02-02 2024-02-02 上海细胞治疗集团有限公司 多肽、含有多肽的组合物及其在肿瘤免疫中的应用
CN112402596B (zh) * 2019-08-22 2023-12-08 上海细胞治疗集团有限公司 多肽组合物及疫苗
JP6782503B1 (ja) * 2019-12-12 2020-11-11 康基 土方 癌治療用細胞組成物を製造する方法、それにより製造される癌治療用細胞組成物、及び癌治療用細胞組成物を用いた癌の治療方法
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
JP2023119754A (ja) * 2022-02-17 2023-08-29 Ｄｃ－Ｂｉｏｔｅｃｈ株式会社 カクテル樹状細胞ワクチンの製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856025B2 (ja) 2012-08-02 2016-02-09 阿部　博幸 単球またはｎｋ細胞を入手する方法

Similar Documents

Publication Publication Date Title
Yaremenko et al. Clinical advances of mRNA vaccines for cancer immunotherapy
Huang et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
Zheng et al. Targeted cancer therapy using engineered Salmonella typhimurium
ES2819861T3 (es) Nueva inmunoterapia contra diversos tumores como el cáncer gastrointestinal y gástrico
Matsiko Cancer immunotherapy making headway
ES2877090T3 (es) Receptor de antígenos quiméricos y células T en las que se expresa el receptor de antígenos quiméricos
JP2013536157A5 (enExample)
ES2460899T3 (es) Inmunoterapia basada en células cancerosas alógenas
Elster et al. Dendritic cell vaccines: A review of recent developments and their potential pediatric application
ES3035716T3 (en) Universal antigen presenting cells and uses thereof
Ding et al. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects
Li et al. Boosting CAR-T cell therapy through vaccine synergy
JP2015533376A5 (enExample)
He et al. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer
Garnett-Benson et al. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities
Loi et al. Radiotherapy in the age of cancer immunology: current concepts and future developments
Proietti et al. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy
Majd et al. Immunotherapy for neuro-oncology
Ge et al. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
Zhang et al. Combined immunotherapy and targeted therapies for cancer treatment: Recent advances and future perspectives
Suzuki et al. Current status of vaccine immunotherapy for gastrointestinal cancers
ES2759015T3 (es) Métodos y materiales para tratar el cáncer
CN115804853A (zh) 包含rna分子的组合物及其在制备瘤内注射剂中的用途
CN106075453A (zh) 一种抗肿瘤药物制剂组合
Feng et al. Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy